Topic Code HORIZON-HLTH-2026-01-IND-03 F&T Portal
Call Identifier HORIZON-HLTH-2026-01 Call 01 — single stage (2026)
Instrument HORIZON-RIA Research and Innovation Action
Budget Model Lump Sum HORIZON-AG-LS
Funding Rate 100% Annex G — RIA = 100%
Page Limit (Part B) 45 pages RIA + lump sum (Annex A)
Evaluation Thresholds 4 / 4 / 4 · cum. 12 Non-standard — topic override
Expected Projects 4 €4–6M per project (WP stated)
Destination Maintaining an innovative, sustainable, and competitive EU health industry WP Part 4
Cluster / Pillar Cluster 1 / Pillar II Health
China Eligibility Excluded ⚠ Destination excludes RIA/IA
Special Conditions Non-standard thresholds ⚠ 4/4/4 cum. 12 — not default 3/3/3
Verify: Open this topic on the F&T Portal →  ·  Sources: General Annexes 2026-2027, WP Part 4
See what a full Decision Brief looks like →
Compliance traps · Scoring playbook · Consortium blueprint · 2 free examples available
Chinese entities are excluded from RIA actions under this destination. Legal entities established in China are not eligible to participate in Research and Innovation Actions (RIAs) falling under Destination ‘Maintaining an innovative, sustainable, and competitive EU health industry’.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
Communication networks restriction: Entities assessed as high-risk suppliers of mobile network communication equipment (and entities they own or control) are not eligible to participate in this topic.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.

Expected Outcomes

  1. Policymakers and regulators will get accelerated access to improved evidence driven methodologies to evaluate the impact and efficiency of novel health technologies, facilitating decision-making for their use in humans and uptake in clinical practice.
  2. Patients and the health systems will benefit from the more targeted and efficient uptake of safe and effective health innovations in clinical practice, supporting more personalised approaches and improved care and public health.

Want the full analysis?

The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.

Compliance traps Scoring playbook Consortium blueprint Positioning guide Red flags Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day
Disclaimer: This page is produced using advanced AI analysis and reviewed by an experienced EU grant engineer. While we take care to ensure accuracy, the information may contain errors or become outdated. It is the applicant’s sole responsibility to verify all facts against the official EU Funding & Tenders Portal before making any decisions. Global Disruption accepts no liability for errors, omissions, or decisions made based on this content. No refunds are offered for Key Facts pages or Decision Briefs.